Lazard Asset Management
BHVN

Lazard Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Lazard Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-449
Closed -$67K – 2647
2022
Q3 		$67K Sell
449
-794
-64% -$118K ﹤0.01% 1667
2022
Q2 		$181K Buy
1,243
+368
+42% +$47K ﹤0.01% 1310
2022
Q1 		$103K Sell
875
-4
-0.5% -$499 ﹤0.01% 1388
2021
Q4 		$121K Sell
879
-8,117
-90% -$1.03M ﹤0.01% 1389
2021
Q3 		$1.25M Buy
8,996
+8,114
+920% +$1.01M ﹤0.01% 1012
2021
Q2 		$85K Buy
882
+776
+732% +$63K ﹤0.01% 1399
2021
Q1 		$7K Sell
106
-514
-83% -$41.6K ﹤0.01% 1781
2020
Q4 		$53K Buy
+620
New +$52.5K ﹤0.01% 1372

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Lazard Asset Management's BHVN Position: Q4 2022 in Review

Lazard Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 449 shares — an estimated $67K sold.

Lazard Asset Management first reported a position in BHVN in Q4 2020 and held it in 8 quarters. The position peaked at $1.25M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Lazard Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Lazard Asset Management sold 449 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $67K.
  • Lazard Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 8 quarters.
  • Lazard Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.25M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Lazard Asset Management's 13F filing for Q4 2022, filed 15 Feb 2023.